Towards Better Sinomenine-Type Drugs to Treat Rheumatoid Arthritis: Molecular Mechanisms and Structural Modification

Molecules. 2022 Dec 7;27(24):8645. doi: 10.3390/molecules27248645.

Abstract

Sinomenine is the main component of the vine Sinomenium acutum. It was first isolated in the early 1920s and has since attracted special interest as a potential anti-rheumatoid arthritis (RA) agent, owing to its successful application in traditional Chinese medicine for the treatment of neuralgia and rheumatoid diseases. In the past few decades, significant advances have broadened our understanding of the molecular mechanisms through which sinomenine treats RA, as well as the structural modifications necessary for improved pharmacological activity. In this review, we summarize up-to-date reports on the pharmacological properties of sinomenine in RA treatment, document their underlying mechanisms, and provide an overview of promising sinomenine derivatives as potential RA drug therapies.

Keywords: autoimmune diseases; inflammatory diseases; rheumatoid arthritis; sinomenine; traditional Chinese medicine.

Publication types

  • Review

MeSH terms

  • Arthritis, Rheumatoid* / drug therapy
  • Humans
  • Medicine, Chinese Traditional
  • Morphinans* / pharmacology
  • Morphinans* / therapeutic use
  • Neuralgia* / drug therapy

Substances

  • sinomenine
  • Morphinans

Grants and funding

This work was funded by the National Key Research and Development Program of China (2020YFA0908000) and the National Natural Science Foundation of China (82173914), with external research funding from the State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University (FAMP202101K).